Bonk, Inc. (NASDAQ:BNKK – Get Free Report) saw a large decline in short interest during the month of July. As of July 31st, there was short interest totaling 193,599 shares, a decline of 36.6% from the July 15th total of 305,481 shares. Approximately 5.0% of the company’s shares are sold short. Based on an average trading volume of 58,461 shares, the short-interest ratio is presently 3.3 days.
Bonk Price Performance
BNKK traded up $0.10 during mid-day trading on Wednesday, hitting $1.03. The stock had a trading volume of 79,141 shares, compared to its average volume of 695,510. The stock’s fifty day simple moving average is $1.25 and its 200-day simple moving average is $2.26. The firm has a market capitalization of $8.26 million, a price-to-earnings ratio of -0.27 and a beta of 1.99. Bonk has a 1-year low of $0.91 and a 1-year high of $18.20.
Bonk (NASDAQ:BNKK – Get Free Report) last announced its quarterly earnings results on Friday, August 14th. The company reported ($0.76) earnings per share (EPS) for the quarter. Bonk had a negative net margin of 952.21% and a negative return on equity of 122.84%. The firm had revenue of $1.16 million during the quarter.
Wall Street Analyst Weigh In
View Our Latest Stock Analysis on Bonk
Institutional Investors Weigh In On Bonk
Large investors have recently modified their holdings of the business. State Street Corp acquired a new stake in shares of Bonk during the fourth quarter worth about $33,000. Steward Partners Investment Advisory LLC bought a new stake in Bonk during the 4th quarter worth approximately $37,000. BlackRock Inc. bought a new stake in Bonk during the 2nd quarter worth approximately $50,000. Jane Street Group LLC acquired a new stake in Bonk during the 4th quarter worth approximately $96,000. Finally, Geode Capital Management LLC acquired a new stake in Bonk during the 4th quarter worth approximately $128,000. 12.55% of the stock is currently owned by institutional investors.
Bonk Company Profile
Safety Shot, Inc, a wellness and functional beverage company, engages in the research and development of over-the-counter products and intellectual property. Its products pipeline includes Photocil to address psoriasis and vitiligo; JW-700 to treat hair loss; JW-500 for women’s sexual wellness; NoStingz, a jellyfish sting prevention sunscreen; and JW-110 for the treatment of atopic dermatitis/eczema. The company primarily sell its products through third-party physical retail stores and partners. The company was formerly known as Jupiter Wellness, Inc and changed its name to Safety Shot, Inc in September 2023.
Further Reading
- Five stocks we like better than Bonk
- Okta’s AI Tailwind Could Put This Forgotten Software Stock Back in Play
- Datavault AI Locks Down CyberCatch in $94M Security Rollup
- Quantum Stocks Are Starting to Choose Sides: Should Investors Do the Same?
- AeroVironment Hit a Bottom in Q2—Can It Take Flight in Q3?
Receive News & Ratings for Bonk Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bonk and related companies with MarketBeat.com's FREE daily email newsletter.
